OakChart

Vanda Pharmaceuticals Inc

VNDAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:35 PM ET

4.16+0.08 (1.84%)
2026-11-11 21:35 CET
Market cap
246.72 USD m
Revenue, TTM
229.28 USD m
Net income, TTM
-274.83 USD m
Free cash flow, TTM
-139.96 USD m
EPS diluted, TTM
-4.62
P/E
-
Compare

Price

VNDA against its 20, 50 and 200-day averages
2050200beatmiss
4.005.006.007.001.5M3.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VNDAclose 4.1620-day 3.9850-day 4.56200-day 6.064.1652w low

58.2% under the 52-week high of 9.94 on 10 Mar 2026. 52-week low 3.57 on 5 Nov 2026. Last 15 sessions, 30.2% high to low

Volume 0.46× normal · the line is the 50-bar volume average

Profile

VNDA
52-week range, 9% of the way up
3.579.94

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

IndexRUT
Employees533
IPOApr 12, 2006
Beta0.72
ATR, 14d0.25
Rel volume0.46
Short float13.33%
Insider own5.40%
Inst own86.13%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap251.26M
Enterprise Value132.74M
Income-274.83M
Sales229.28M
Book/sh3.31
Cash/sh2.32
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees533
IPOApr 12, 2006

Ratios

P/E-
Forward P/E-
PEG-
P/S1.10
P/B1.26
P/C1.79
P/FCF-
EV/EBITDA-
EV/Sales0.58
Quick Ratio1.53
Current Ratio1.54
Debt/Eq0.11
LT Debt/Eq0.09
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.62
EPS next Y-0.74
EPS next Q-0.30
EPS this Y32.51%
EPS next Y70.76%
EPS next 5Y47.86%
EPS past 3/5Y- -
Sales past 3/5Y-5.29% -2.73%
EPS Y/Y TTM-222.50%
Sales Y/Y TTM8.11%
EPS Q/Q2.38%
Sales Q/Q24.10%
EarningsOct 28 AMC
EPS/Sales Surpr.45.75% 0.89%

Ownership

Insider Own5.40%
Insider Trans0.31%
Inst Own86.13%
Inst Trans2.66%
ROA-55.89%
ROE-82.55%
ROIC-126.56%
Gross Margin89.33%
Oper. Margin-77.59%
Profit Margin-119.87%
SMA204.38%
SMA50-8.81%
SMA200-31.41%
Trades-

Technical

Shs Outstand60.47M
Shs Float57.21M
Short Float13.33%
Short Ratio7.21
Short Interest7.62M
52W High9.94 -58.20%
52W Low3.57 16.55%
Volatility7.06% 6.81%
ATR (14)0.25
RSI (14)49.97
Beta0.72
Rel Volume0.46
Avg Volume1.06M
Volume457,113

Performance

Perf Week7.09%
Perf Month-3.37%
Perf Quarter-17.40%
Perf Half Y-35.38%
Perf YTD-52.89%
Perf Year-5.14%
Perf 3Y21.85%
Perf 5Y-77.11%
Perf 10Y-74.89%
Recom1.40
Target Price11.50
Prev Close4.08
Price4.16
Change %1.84%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 23, 2026InitiatedOOppenheimerOutperform$10+140.7%
Mar 05, 2026InitiatedTTruistBuy$18+333.2%
Nov 05, 2025InitiatedRB. Riley SecuritiesBuy$11+164.7%
Oct 31, 2024InitiatedHH.C. WainwrightBuy$18+333.2%
Jul 11, 2024InitiatedCCantor FitzgeraldOverweight$11+164.7%
Feb 25, 2022DowngradeJJefferiesBuy → Hold$24 → $12+188.8%
May 12, 2021InitiatedBBofA SecuritiesBuy$22+429.5%
Jan 14, 2021DowngradeCCitigroupBuy → Neutral$14+236.9%
Oct 29, 2020UpgradeCCitigroupNeutral → Buy$14+236.9%
Jun 09, 2020DowngradeCCitigroupBuy → Neutral$14+236.9%

Peers

Mkt cap
TickerCompanyMkt cap
HRMYHarmony Biosciences Holdings Inc2.01B
ACADAcadia Pharmaceuticals Inc3.19B
AXSMAxsome Therapeutics Inc7.82B
JAZZJazz Pharmaceuticals plc15.94B
SUPNSupernus Inc6.08B
ALKSAlkermes plc8.04B
NERVMinerva Neurosciences Inc126.05M
LBRXLB Pharmaceuticals Inc1.44B
NBIXNeurocrine Biosciences Inc17.60B
BIIBBiogen Inc37.65B

Insider trading

latest 14 of 15
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Duncan Charles CliffDirectorNov 05 '26Buy3.805,80322,076108,701Nov 05 04:16 PM
Duncan Charles CliffDirectorNov 04 '26Buy3.823,44713,171102,898Nov 05 04:16 PM
Duncan Charles CliffDirectorNov 03 '26Buy3.807502,84799,451Nov 05 04:16 PM
Williams TimothySVP & General CounselMar 02 '26Sale8.2742,434350,755377,450Mar 04 06:54 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 02 '26Sale8.2742,442350,821411,380Mar 04 06:53 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 02 '26Sale8.2730,800254,590333,469Mar 04 06:52 PM
Polymeropoulos Mihael HristosPresident and CEOMar 02 '26Sale8.17156,2351,276,9712,704,496Mar 04 06:51 PM
Birznieks GuntherSVP, Business DevelopmentMar 02 '26Sale8.2742,431350,730494,197Mar 04 06:51 PM
Timothy WilliamsSVP & General CounselMar 02 '26Proposed Sale8.2742,434350,755Mar 02 09:43 PM
Gunther BirznieksSVP, Business DevelopmentMar 02 '26Proposed Sale8.2742,431350,730Mar 02 09:27 PM
Joakim WijkstromSVP, Chief Marketing OfficerMar 02 '26Proposed Sale8.2730,800254,589Mar 02 09:18 PM
Mihael H. PolymeropoulosOfficerMar 02 '26Proposed Sale8.17156,2351,276,976Mar 02 09:15 PM
Kevin MoranSVP, CFO & TreasurerMar 02 '26Proposed Sale8.2742,442350,821Mar 02 09:09 PM
Honore TageDirectorFeb 23 '26Sale8.0330,000240,90093,469Feb 24 04:28 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IBBiShares Biotechnology ETFAUM: 11.36B
DFSVUS Small Cap Value Portfolio ETF Class SharesAUM: 8.52B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-28-0.370-0.682-0.37069.8269.205
2026Q22026-08-05-1.040-0.583-1.03850.5361.934
2026Q12026-05-06-0.820-0.688-0.81751.7254.985
2025Q42026-02-11-2.390-0.975-2.38957.2259.284
2025Q32025-10-29-0.380-0.433-0.38256.2658.833
2025Q22025-07-31-0.460-0.357-0.46152.5954.773
2025Q12025-05-07-0.500-0.573-0.50450.0445.133
2024Q42025-02-13-0.080-0.107-0.08453.1952.253
2024Q32024-11-06-0.090-0.157-0.09147.6549.173
2024Q22024-07-31-0.080-0.190-0.07850.4747.901
2024Q12024-05-08-0.0700.050-0.07247.4648.501
2023Q42024-02-07-0.040-0.090-0.04245.2737.001
2023Q32023-11-080.000-0.0400.00238.8244.501
2023Q22023-07-270.030-0.1300.02646.0649.001
2023Q12023-05-030.060-0.05762.50--
2022Q42023-02-080.1200.0800.12064.4867.601

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY2.1101.1802.107227.19225.8
2020FY0.4200.4600.423248.17244.5
2021FY0.5800.5550.582268.68270.72
2022FY0.1100.0500.110254.38257.5
2023FY0.040-0.0100.044192.64184.4
2024FY-0.330-0.317-0.325198.77199.45
2025FY-3.740-2.673-3.740216.11218.27
2026FY--2.524--242.13
2027FY--0.738--316.18
2028FY--0.530--358.33
2029FY-0.153--438.1
2030FY-0.473--490.2

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-3051470.0868.8871.00
2026Q4S2026-10-2950469.8868.8871.00
2026Q4S2026-10-2850174.9870.0080.20
2026Q4S2026-10-2150077.4270.0083.20
2026Q4S2026-10-2050177.4270.0083.20
2026Q4S2026-09-2251277.4270.0083.20
2026Q4S2026-08-0741277.1070.0083.20
2026Q4S2026-08-0641178.3575.0083.20
2026Q4S2026-07-2240079.2375.0081.20
2026Q4S2026-07-2141079.2375.0081.20
2026Q4S2026-06-1143079.2375.0081.20
2026Q4S2026-05-0854080.0075.0083.10
2026Q4S2026-05-0753079.4072.0083.10
2026Q4S2026-04-2951073.7871.1080.00

Estimate history

EPS, annual-0.3480.4752.1070.4230.5820.110.044-0.325-3.741-4.6169
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.091-0.084-0.504-0.461-0.382-2.389-0.817-1.038-0.373
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual165.083193.118227.188248.168268.682254.382192.64198.772216.105229.28
Period201720182019202020212022202320242025TTM
Sales, quarterly47.65153.18550.04152.5956.25857.21651.71850.52969.815
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual44.93852.47853.5554.86555.90156.78457.53458.31159.10260.469
Period201720182019202020212022202320242025MRQ
Shares, quarterly58.30658.31158.93459.08159.09659.10260.13560.45560.469
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue229.28216.10198.77192.64254.38268.68248.17227.19193.12
Cost of Goods Sold Incl. D&A24.4720.0518.5916.8925.8027.1124.8425.9922.04
Gross Profit204.81196.05180.19175.75228.58241.57223.33201.19171.08
Selling, General and Administrative Excl. Other382.71347.22220.84189.71222.25199.41196.09178.38149.34
Research and Development122.02109.2774.4376.8285.7775.3655.5848.6543.59
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-177.91-151.17-40.66-13.956.3342.1627.2422.8121.74
Interest Expense---0.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-171.20-138.65-22.926.3411.3042.3631.6629.0325.35
Income Taxes103.6381.83-4.023.835.039.218.32-86.530.14
Consolidated Net Income-274.83-220.47-18.902.516.2833.1523.34115.5525.21
Net Income From Continuing Operations-274.83-220.47-18.902.516.2833.1523.34115.5525.21
Net Income-274.83-220.47-18.902.516.2833.1523.34115.5525.21
EPS (Recurring)-4.55-3.74-0.330.040.110.580.422.110.48
EPS (Basic, Before Extraordinaries)-4.62-3.74-0.330.040.110.600.432.170.50
EPS (Diluted)-4.62-3.74-0.330.040.110.580.422.110.48
EBITDA-161.25-139.25-32.53-10.949.0645.0130.1025.7024.69
Non-Operating Income (Expense)6.7112.5217.7420.294.970.204.426.223.61
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.347.489.8211.0912.8611.229.759.829.22
Price To Earnings Ratio---20.5566.1026.9331.137.7555.86
Price To Sales Ratio1.292.411.401.261.663.322.923.967.18
Gross Margin89.3390.7290.6591.2389.8689.9189.9988.5688.59
Operating Margin-77.59-69.95-20.46-7.242.4915.6910.9810.0411.26
Net Margin-119.87-102.02-9.511.302.4712.349.4050.8613.05
Shares Outstanding60.4759.1058.3157.5356.7855.9054.8753.5552.48
Market Capitalization246.72246.72279.30242.78418.20874.12718.65875.261,370.52

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue69.8150.5351.7257.2256.2652.5950.0453.19
Cost of Goods Sold Incl. D&A6.145.555.157.644.714.495.274.34
Gross Profit63.6844.9846.5749.5851.5548.1044.7748.84
Selling, General and Administrative Excl. Other87.20108.7996.8089.9382.8486.6185.8059.12
Research and Development27.6236.9528.4329.0122.5621.9935.7119.84
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-23.52-63.81-50.22-40.35-31.28-38.50-41.03-10.28
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-22.39-62.38-48.42-38.00-28.39-34.89-37.37-6.50
Income Taxes0.170.130.14103.19-5.80-7.68-7.87-1.58
Consolidated Net Income-22.56-62.51-48.57-141.19-22.59-27.21-29.49-4.91
Net Income From Continuing Operations-22.56-62.51-48.57-141.19-22.59-27.21-29.49-4.91
Net Income-22.56-62.51-48.57-141.19-22.59-27.21-29.49-4.91
EPS (Recurring)-0.37-1.04-0.82-2.39-0.38-0.46-0.50-0.08
EPS (Basic, Before Extraordinaries)-0.37-1.04-0.82-2.39-0.38-0.46-0.50-0.08
EPS (Diluted)-0.37-1.04-0.82-2.39-0.38-0.46-0.50-0.08
EBITDA-19.96-60.10-46.70-34.49-29.23-36.48-39.05-8.31
Non-Operating Income (Expense)1.131.431.802.352.893.623.663.78
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.851.662.021.811.671.662.352.26
Price To Sales Ratio1.291.711.892.411.391.371.331.41
Gross Margin91.2189.0290.0586.6591.6391.4789.4691.84
Operating Margin-33.69-126.28-97.11-70.53-55.61-73.21-81.99-19.33
Net Margin-32.32-123.72-93.91-246.76-40.15-51.73-58.94-9.24
Shares Outstanding60.4760.4560.1459.1059.1059.0858.9358.31
Market Capitalization246.72368.03408.44521.23294.85278.17267.67279.30

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments263.95374.64388.26466.86432.81367.80312.13257.46143.41
Short Term Receivables54.5847.1034.1633.5132.4730.0426.3728.7817.60
Inventories1.851.731.361.191.021.281.140.990.84
Other Current Assets26.8815.429.1717.7312.0010.0314.5011.908.00
Total Current Assets347.26438.89432.95519.29478.30409.14354.14299.13169.86
Net Property, Plant & Equipment13.5112.689.1410.9712.3814.6015.044.425.31
Total Investments and Advances0.370.470.470.470.520.530.580.600.00
Intangible Assets117.09114.10121.3718.5720.0821.5623.0424.5426.07
Deferred Tax Assets0.0081.4475.0074.0474.8881.5287.68-0.00
Other Assets10.728.639.5210.917.636.123.273.444.19
Total Assets488.95656.20648.44634.25593.79533.46483.75332.13205.43
Short Term Debt Incl. Current Port. of LT Debt5.554.272.402.332.312.122.150.000.00
Accounts Payable7.005.169.5517.676.805.825.905.174.39
Other Current Liabilities132.6190.5575.7571.4465.3158.0051.4547.8465.97
Total Current Liabilities145.1699.9887.7091.4474.4265.9459.5153.0270.36
Long Term Debt7.078.097.018.8110.0511.5012.460.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-------0.100.10
Other Liabilities9.539.598.836.804.392.760.843.593.58
Total Liabilities161.76117.66103.53107.0588.8680.1972.8056.7174.04
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity327.19538.55544.91527.20504.93453.27410.94275.42131.39
Total Shareholders Equity327.19538.55544.91527.20504.93453.27410.94275.42131.39
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity327.19538.55544.91527.20504.93453.27410.94275.42131.39
Total Liabilities & Stockholders Equity488.95656.20648.44634.25593.79533.46483.75332.13205.43
Book Value Per Share5.549.249.479.289.038.267.675.252.92
Tangible Book Value Per Share3.557.287.368.968.677.877.244.782.34
Full-Time Employees533368203290278292284270273
Price to Book Ratio1.230.520.450.811.741.592.144.985.23
Return on Assets-38.51-2.900.391.025.884.5928.339.38-7.49
Return on Equity-50.93-3.490.471.226.925.4033.6712.39-11.85
Return on Invested Capital-65.96-3.460.451.176.445.0227.299.15-11.85
Quick Ratio2.384.374.925.676.416.195.935.622.40
Current Ratio2.394.394.945.686.436.215.955.642.41

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-274.83-220.47-18.902.516.2833.1523.34115.5525.21
Depreciation16.6611.928.133.012.732.842.862.892.96
Other Funds (Non Cash)7.599.368.059.3115.7718.7415.0712.149.61
Funds from Operations-147.40-117.75-9.2013.5525.9161.4847.4642.8237.78
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital8.268.31-6.56-0.756.072.744.323.12-7.79
Cash from Operating Activities-139.14-109.44-15.7612.8031.9864.2151.7745.9529.99
Capital Expenditures-10.82-1.00-0.49-0.38-0.68-0.55-1.79-1.02-25.37
Net Assets From Acquisitions-0.00-4.23-100.670.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments144.9495.86-12.7188.9950.60-76.14-39.70-67.29-84.29
Purchase of Investments-2.03-112.38-364.77-512.61-349.26-420.46-346.62-394.52-282.39
Sale Or Maturity of Investments146.97208.24352.06601.60399.86344.32306.92327.23198.10
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities134.1294.86-17.43-12.0649.92-76.70-41.50-68.31-109.66
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.733.555.636.26107.13
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.733.555.636.26107.13
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.00100.87
Issuance or Reduction of Debt, Net-3.15-1.99-0.150.000.000.000.000.000.00
Change in Long Term Debt-3.15-1.99-0.150.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-3.15-1.99-0.150.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.920.000.000.000.000.000.000.00
Other Financing Activities Uses0.00-0.920.000.000.000.000.000.000.00
Cash from Financing Activities-3.15-2.91-0.150.000.733.555.636.26107.13
Exchange Rate Effect-0.020.02-0.160.050.27-0.090.05-0.00-0.04
Net Change in Cash-8.19-17.46-33.510.7982.91-9.0215.96-16.1027.41
Free Cash Flow-139.96-110.44-16.2512.4231.3063.6649.9844.9329.62
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow---19.5613.4514.0314.5120.0346.80
Deferred Taxes & Investment Tax Credit-81.44-6.48-1.291.136.756.19-87.770.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments140.49170.13202.31263.95293.75325.55
Short Term Receivables60.3259.6956.8854.5850.5444.99
Inventories1.531.681.701.852.042.17
Other Current Assets36.1332.9832.2826.8821.1622.21
Total Current Assets238.47264.48293.17347.26367.50394.92
Net Property, Plant & Equipment23.2023.9514.0613.5111.9012.47
Total Investments and Advances0.360.370.370.370.370.47
Intangible Assets111.13113.11115.10117.09108.84110.59
Deferred Tax Assets---0.00103.0797.14
Other Assets9.1610.5510.8210.729.469.15
Total Assets382.33412.47433.52488.95601.14624.75
Short Term Debt Incl. Current Port. of LT Debt4.684.636.025.554.694.68
Accounts Payable10.5410.966.317.005.084.00
Other Current Liabilities139.76148.44123.25132.61108.10112.81
Total Current Liabilities154.98164.03135.58145.16117.87121.49
Long Term Debt17.2918.207.057.076.236.96
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities10.2010.0510.139.5311.049.97
Total Liabilities182.47192.28152.76161.76135.14138.42
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity199.86220.19280.76327.19466.00486.33
Total Shareholders Equity199.86220.19280.76327.19466.00486.33
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity199.86220.19280.76327.19466.00486.33
Total Liabilities & Stockholders Equity382.33412.47433.52488.95601.14624.75
Book Value Per Share3.313.644.675.547.898.23
Tangible Book Value Per Share1.471.772.753.556.046.36
Full-Time Employees---533--
Price to Book Ratio1.231.311.251.120.610.54
Return on Assets-55.89-53.00-44.97-38.51-13.51-10.49
Return on Equity-82.55-77.81-60.48-50.93-16.72-13.01
Return on Invested Capital-10.39-26.22-16.87-42.24-4.78-5.52
Quick Ratio1.531.602.152.383.103.23
Current Ratio1.541.612.162.393.123.25

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-22.56-62.51-48.57-141.19-22.59-27.21
Depreciation3.563.713.535.862.052.02
Other Funds (Non Cash)2.632.562.71-0.303.012.59
Funds from Operations-16.37-56.25-42.33-32.44-23.50-30.57
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-12.0725.18-7.883.03-8.1315.32
Cash from Operating Activities-28.43-31.07-50.22-29.42-31.63-15.25
Capital Expenditures-0.31-10.19-0.22-0.10-0.16-0.30
Net Assets From Acquisitions---10.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments35.5234.0030.4544.9721.52-14.97
Purchase of Investments0.000.000.00-2.03-14.05-52.97
Sale Or Maturity of Investments35.5234.0030.4547.0035.5738.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities35.2133.8120.2344.8721.36-15.27
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.88-0.86-0.78-0.64-0.52-0.42
Change in Long Term Debt-0.88-0.86-0.78-0.64-0.52-0.42
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.88-0.86-0.78-0.64-0.52-0.42
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.88-0.86-0.78-0.64-0.52-0.42
Exchange Rate Effect0.05-0.04-0.060.02-0.180.13
Net Change in Cash5.951.85-30.8214.83-10.96-30.81
Free Cash Flow-28.75-31.26-50.44-29.52-31.79-15.55

Revenue breakdown

Fanapt2024: 94.30M 2025: 117.30M
Hetlioz2024: 76.68M 2025: 71.43M
PONVORY2024: 27.80M 2025: 27.37M
United States2024: 198.77M 2025: 216.11M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.33%7.6M57.2M1.04M
2026-10-1514.53%8.3M57.2M968.79K
2026-09-3013.69%7.8M57.2M939.92K
2026-09-1514.85%8.5M57.2M891.97K
2026-08-3113.44%7.7M57.2M922.68K
2026-08-1413.41%7.7M57.2M961.51K
2026-07-3112.98%7.4M57.2M971.78K
2026-07-1512.64%7.2M56.9M1.02M
2026-06-3012.91%7.3M56.9M1.06M
2026-06-1512.29%7.0M56.9M1.29M
2026-05-2911.99%6.8M56.8M1.46M
2026-05-1511.21%6.4M56.8M2.50M
2026-04-3011.27%6.2M55.0M2.52M
2026-04-1510.35%5.6M54.1M2.49M
2026-03-319.82%5.3M54.1M2.66M
2026-03-135.92%3.2M54.1M2.91M
2026-02-278.04%4.3M54.1M2.80M
2026-02-136.42%3.5M54.1M1.78M
2026-01-305.85%3.2M55.1M1.67M
2026-01-155.79%2.9M49.7M1.65M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.002.303.900.0019.3130.000.000.976-0.0400.000
call2.000.802.850.009.1310.000.000.892-0.0650.001
call3.000.801.550.833.8871.000.000.793-0.0610.002
call4.000.000.400.231.2551,5030.000.617-0.0370.002
call5.000.000.100.032.0634630.000.334-0.0270.002
call6.000.000.050.051.68920020.000.106-0.0110.001
call7.000.000.950.152.1631.000.000.088-0.0130.001
call8.000.000.750.002.5850.000.000.077-0.0140.001
call9.000.000.950.002.9190.000.000.071-0.0140.001
call10.000.000.050.003.1050.000.000.066-0.0140.001
put1.000.001.750.0019.3490.000.00-0.024-0.0400.000
put2.000.001.750.009.5760.000.00-0.107-0.0650.001
put3.000.001.750.015.83212.000.00-0.208-0.0610.002
put4.000.000.750.453.2773060.00-0.385-0.0360.002
put5.000.551.251.172.6521400.00-0.781-0.0140.002
put6.000.502.351.973.9551.000.00-0.894-0.0110.001
put7.001.305.300.009.9640.000.00-0.913-0.0120.001
put8.003.104.700.006.3620.000.00-0.923-0.0120.001
put9.004.305.500.006.2780.000.00-0.929-0.0130.001
put10.003.506.900.008.0860.000.00-0.934-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-27SCHEDULE 13GSEC
2026-10-09SCHEDULE 13G/ASEC
2026-08-19SCHEDULE 13GSEC
2026-08-13SCHEDULE 13GSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-083Initial statement of beneficial ownership of securities2026-06-04SEC
2026-06-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-058-KCurrent report2026-06-04SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-12SCHEDULE 13GSEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-05-05EFFECTEffectiveness filing by commission orderSEC
2026-04-29SCHEDULE 13G/ASEC
2026-04-244Statement of changes in beneficial ownership of securities2026-04-22SEC
2026-04-243Initial statement of beneficial ownership of securities2026-04-22SEC
2026-04-24CORRESPSEC
2026-04-23ARSAnnual report to security holders. 2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1138.09K300
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-03002.58M5
2026-0200240.90K1
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.12.73%
STATE STREET CORP5.85%
AQR CAPITAL MANAGEMENT LLC5.82%
RENAISSANCE TECHNOLOGIES LLC5.72%
VANGUARD CAPITAL MANAGEMENT LLC4.20%
AIGH Capital Management LLC3.72%
ACADIAN ASSET MANAGEMENT LLC2.94%
DIMENSIONAL FUND ADVISORS LP2.89%
MILLENNIUM MANAGEMENT LLC2.67%
TWO SIGMA INVESTMENTS, LP2.24%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.81%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.93%
iShares Russell 2000 ETF2.33%
Federated Hermes MDT Small Cap Core Fund1.80%
BlackRock Advantage Small Cap Core Fund1.23%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
Fidelity Small Cap Index Fund0.97%
iShares Russell 2000 Value ETF0.86%
iShares Biotechnology ETF0.67%
U.S. SMALL CAP VALUE PORTFOLIO0.55%

OakChart. VNDA. Cached 15 minutes.